The Opioid Epidemic and Psychiatry: The Time for Action Is Now

被引：5

作者：

Brunette, Mary F. ^{[1
,2
]}

Oslin, David W. ^{[1
,3
,4
]}

Dixon, Lisa B. ^{[1
,5
,6
]}

Adler, David A. ^{[1
,7
]}

Berlant, Jeffrey ^{[1
,8
]}

Erlich, Matthew ^{[1
,5
,6
]}

First, Michael B. ^{[1
,5
,6
]}

Goldman, Beth ^{[1
]}

Levine, Bruce ^{[1
]}

Siris, Samuel ^{[1
,9
]}

Winston, Helena ^{[1
,10
]}

机构：

[1] Grp Adv Psychiat, Dallas, TX 75357 USA

[2] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH 03755 USA

[3] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA

[4] Philadelphia Vet Adm Med Ctr, Philadelphia, PA USA

[5] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Dept Psychiat, New York, NY USA

[6] New York State Psychiat Inst & Hosp, New York, NY 10032 USA

[7] Tufts Med Ctr, Dept Psychiat, Boston, MA 02111 USA

[8] Optum Idaho, Boise, ID USA

[9] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Psychiat, New York, NY USA

[10] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA

来源：

PSYCHIATRIC SERVICES | 2019年 / 70卷 / 12期

关键词：

USE DISORDER; UNITED-STATES; BUPRENORPHINE; PHYSICIANS; ALCOHOL;

D O I：

10.1176/appi.ps.201800582

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The number of people with opioid use disorder and the number of overdose deaths in the United States have increased dramatically over the past 20 years. U.S. Congress passed the SUPPORT for Patients and Communities Act, which was signed into law in 2018, authorizing almost $8 billion to address the crisis. As experts in the treatment of central nervous systems disorders, psychiatrists can play a leading role in expanding treatment for people with opioid use disorder and in advocating for policy changes to support community treatment for this group.

引用

页码：1167 / 1170

页数：4

共 14 条

[1]

[Anonymous], 2013, ADDR PRESCR DRUG AB

[2] Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact [J].

Brooklyn, John R. ;

Sigmon, Stacey C. .

JOURNAL OF ADDICTION MEDICINE, 2017, 11 (04) :286-292

[3]

DRAKE RE, 1989, HOSP COMMUNITY PSYCH, V40, P1041

[4] Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015 [J].

Guy, Gery P., Jr. ;

Zhang, Kun ;

Bohm, Michele K. ;

Losby, Jan ;

Lewis, Brian ;

Young, Randall ;

Murphy, Louise B. ;

Dowell, Deborah .

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2017, 66 (26) :697-704

[5] Why aren't physicians prescribing more buprenorphine? [J].

Huhn, Andrew S. ;

Dunn, Kelly E. .

JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2017, 78 :1-7

[6]

Iyiewuare PO, 2017, HEALTH SERV RES MANA, V4, DOI 10.1177/2333392817734523

[7] Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III [J].

Kerridge, Bradley T. ;

Saha, Tulshi D. ;

Chou, S. Patricia ;

Zhang, Haitao ;

Jung, Jeesun ;

Ruan, W. June ;

Smith, Sharon M. ;

Huang, Boji ;

Hasin, Deborah S. .

DRUG AND ALCOHOL DEPENDENCE, 2015, 156 :47-56

[8] The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis [J].

Knudsen, Hannah K. .

JOURNAL OF STUDIES ON ALCOHOL AND DRUGS, 2015, 76 (04) :644-654

[9] Changes in US Lifetime Heroin Use and Heroin Use Disorder Prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions [J].

Martins, Silvia S. ;

Sarvet, Aaron ;

Santaella-Tenorio, Julian ;

Saha, Tulshi ;

Grant, Bridget F. ;

Hasin, Deborah S. .

JAMA PSYCHIATRY, 2017, 74 (05) :445-455

[10] Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population [J].

Morgan, Jake R. ;

Schackman, Bruce R. ;

Leff, Jared A. ;

Linas, Benjamin P. ;

Walley, Alexander Y. .

JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 85 :90-96

← 1 2 →